Abstract
The inflammatory bowel diseases (IBD); Crohn’s and Ulcerative colitis, result from an altered host response to intestinal flora. Recurrent inflammation with ulceration and tissue restitution confers an increased risk of cancer in both UC and Crohns, and genome wide searches have identified a number of disease susceptibility alleles. The carcinogenesis pathway in colitis-associated colorectal cancer (CACRC) is less clearly understood than it’s sporadic counterpart. Clonal ordering experiments have indicated the order and timing of chromosomal instability and common genetic mutations. Epigenetic changes such as DNA methylation and histone modification are thought to play an increasingly important role in inflammation induced carcinogenesis. Clonal expansion of procarcinogenic mutations can lead to large fields of mutant tissue from which colitis associated cancers can arise (field cancerisation). Endoscopic screening is the mainstay of surveillance in high-risk patients although the development of appropriate, clinically applicable biomarkers remains a research priority. Despite the expanding field of biological therapy in inflammatory bowel disease the ASA compounds remain the best-studied and most efficacious chemopreventive agents. Colitis associated CRC appears to have a different aetiology, carcinogenesis pathway and clinical course to its sporadic counterpart. Further research including long-term follow up of patient cohorts taking biological therapies will improve the detection and treatment of these important, inflammation-induced malignancies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen DC, Biggart JD, Pyper PC (1985) Large bowel mucosal dysplasia and carcinoma in ulcerative colitis. J Clin Pathol 38:30–43
Allgayer H (2003) Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18(suppl 2):10–14
Asano K, Matsushita T, Umeno J et al (2009) A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet 41:1325–1329
Bamba S, Lee CY, Brittan M et al (2006) Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J Pathol 209:265–273
Barrett JC, Lee JC, Lees CW et al (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41:1330–1334
Befrits R, Hammarberg C, Rubio C et al (1994) DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum 37:313–319 discussion 319-20
Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S et al (2008) European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohn’s Colitis 2:63–92
Bodmer W (2008) Genetic instability is not a requirement for tumor development. Cancer Res 68:3558–3560 discussion 3560-1
Bos CL, Diks SH, Hardwick JC et al (2006) Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27:2371–2382
Braakhuis BJ, Tabor MP, Kummer JA et al (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727–1730
Brentnall TA, Crispin DA, Rabinovitch PS et al (1994) Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107:369–378
Brittan M, Hunt T, Jeffery R et al (2002) Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut 50:752–757
Brittan M, Chance V, Elia G et al (2005) A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology 128:1984–1995
Burmer GC, Rabinovitch PS, Haggitt RC et al (1992) Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103:1602–1610
Cao D, Bromberg PA, Samet JM (2007) COX-2 expression induced by diesel particles involves chromatin modification and degradation of HDAC1. Am J Respir Cell Mol Biol 37:232–239
Chen R, Rabinovitch PS, Crispin DA et al (2003) DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 162:665–672
Chen R, Bronner MP, Crispin DA et al (2005a) Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions. Cancer Genet Cytogenet 162:99–106
Chen R, Rabinovitch PS, Crispin DA et al (2005b) The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis 26:1513–1519
Cho JH, Nicolae DL, Gold LH et al (1998) Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 95:7502–7507
Dekker E, van den Broek FJ, Reitsma JB et al (2007) Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 39:216–221
Direkze NC, Hodivala-Dilke K, Jeffery R et al (2004) Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 64:8492–8495
Dubuquoy L, Rousseaux C, Thuru X et al (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341–1349
Duerr RH, Barmada MM, Zhang L et al (2000) High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11–12. Am J Hum Genet 66:1857–1862
Eaden JA, Mayberry JF (2002) Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51(Suppl 5):V10–V12
East JE, Suzuki N, von Herbay A et al (2006) Narrow band imaging with magnification for dysplasia detection and pit pattern assessment in ulcerative colitis surveillance: a case with multiple dysplasia associated lesions or masses. Gut 55:1432–1435
Ekbom A, Helmick C, Zack M et al (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323:1228–1233
Fellermann K, Stange DE, Schaeffeler E et al (2006) A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79:439–448
Ferrari SL, Ahn-Luong L, Garnero P et al (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88:255–259
Fisher SA, Tremelling M, Anderson CA et al (2008) Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn’s disease. Nat Genet 40:710–712
Franke A, Balschun T, Karlsen TH et al (2008) Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40:1319–1323
Garcia-Olmo D, Garcia-Arranz M, Herreros D et al (2005) A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48:1416–1423
Gillen CD, Walmsley RS, Prior P et al (1994) Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35:1590–1592
Greaves LC, Preston SL, Tadrous PJ et al (2006) Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci USA 103:714–719
Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296
Hampe J, Schreiber S, Shaw SH et al (1999) A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 64:808–816
Hasko G, Szabo C, Nemeth ZH et al (2001) Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 103:473–478
Huang Z, Li L, Wang J (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52:2287–2291
Hugot JP, Laurent-Puig P, Gower-Rousseau C et al (1996) Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 379:821–823
Hussain SP, Amstad P, Raja K et al (2000) Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60:3333–3337
Imielinski M, Baldassano RN, Griffiths A et al (2009) Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 41:1335–1340
Issa JP, Ahuja N, Toyota M et al (2001) Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61:3573–3577
Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17
Keller R, Foerster EC, Kohler A et al (2001) Diagnostic value of DNA image cytometry in ulcerative colitis. Dig Dis Sci 46:870–878
Kennedy M, Wilson L, Szabo C et al (1999) 5-aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med 4:437–443
Kim KM, Shibata D (2002) Methylation reveals a niche: stem cell succession in human colon crypts. Oncogene 21:5441–5449
Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170
Kukitsu T, Takayama T, Miyanishi K et al (2008) Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin Cancer Res 14:48–54
Lanzoni G, Roda G, Belluzzi A et al (2008) Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol 14:4616–4626
Leedham SJ, Graham TA, Oukrif D et al (2009) Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 136:542–506
Loeb KR, Loeb LA (1999) Genetic instability and the mutator phenotype. Studies in ulcerative colitis. Am J Pathol 154:1621–1626
Lofberg R, Brostrom O, Karlen P et al (1992) DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102:1149–1154
Lyda MH, Noffsinger A, Belli J et al (1998) Multifocal neoplasia involving the colon and appendix in ulcerative colitis: pathological and molecular features. Gastroenterology 115:1566–1573
Lyda MH, Noffsinger A, Belli J et al (2000) Microsatellite instability and K-ras mutations in patients with ulcerative colitis. Hum Pathol 31:665–671
Ma Y, Ohmen JD, Li Z et al (1999) A genome-wide search identifies potential new susceptibility loci for Crohn’s disease. Inflamm Bowel Dis 5:271–278
Macarthur M, Sharp L, Hold GL et al (2005) The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14:1613–1618
Moum B, Ekbom A, Vatn MH et al (1999) Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 94:1564–1569
Nakamizo A, Marini F, Amano T et al (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307–3318
O’Sullivan JN, Bronner MP, Brentnall TA et al (2002) Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 32:280–284
Park HS, Goodlad RA, Wright NA (1995) Crypt fission in the small intestine and colon. A mechanism for the emergence of G6PD locus-mutated crypts after treatment with mutagens. Am J Pathol 147:1416–1427
Powell SM, Zilz N, Beazer-Barclay Y et al (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359:235–237
Rioux JD, Silverberg MS, Daly MJ et al (2000) Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 66:1863–1870
Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 13:1024–1030
Rousseaux C, Lefebvre B, Dubuquoy L et al (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201:1205–1215
Rubin CE, Haggitt RC, Burmer GC et al (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103:1611–1620
Rutgeerts P, Vermeire S, Van Assche G (2009) Biological therapies for inflammatory bowel diseases. Gastroenterology 136:1182–1197
Rutter M, Saunders B, Wilkinson K et al (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126:451–459
Satsangi J, Parkes M, Louis E et al (1996) Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 14:199–202
Seril DN, Liao J, Yang GY et al (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24:353–362
Shivananda S, Lennard-Jones J, Logan R et al (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39:690–697
Sieber OM, Heinimann K, Gorman P et al (2002) Analysis of chromosomal instability in human colorectal adenomas with two mutational hits at APC. Proc Natl Acad Sci USA 99:16910–16915
Slattery ML, Wolff RK, Herrick JS et al (2007) IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18:1095–1105
Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963–968
Studeny M, Marini FC, Champlin RE et al (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603–3608
Swidsinski A, Weber J, Loening-Baucke V et al (2005) Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 43:3380–3389
Tomlinson I, Bodmer W (1999) Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 5:11–12
van den Broek FJ, Fockens P, van Eeden S et al (2008) Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 57:1083–1089
Velayos F (2008) Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices. Expert Rev Gastroenterol Hepatol 2:817–825
Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532
von Roon AC, Karamountzos L, Purkayastha S et al (2007) Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 102:803–813
Wahl C, Liptay S, Adler G et al (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101:1163–1174
Willenbucher RF, Zelman SJ, Ferrell LD et al (1997) Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 113:791–801
Winawer S, Fletcher R, Rex D et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124:544–560
Yin J, Harpaz N, Tong Y et al (1993) p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104:1633–1639
Yoshida T, Mikami T, Mitomi H et al (2003) Diverse p53 alterations in ulcerative colitis-associated low-grade dysplasia: full-length gene sequencing in microdissected single crypts. J Pathol 199:166–175
Zimmerman MJ, Jewell DP (1996) Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther 10 (suppl 2):93–98 discussion 99
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Velag Berlin Heidelberg
About this chapter
Cite this chapter
Jawad, N., Direkze, N., Leedham, S.J. (2011). Inflammatory Bowel Disease and Colon Cancer. In: Jankowski, J. (eds) Inflammation and Gastrointestinal Cancers. Recent Results in Cancer Research, vol 185. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-03503-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-03503-6_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-03502-9
Online ISBN: 978-3-642-03503-6
eBook Packages: MedicineMedicine (R0)